WuXi Biologics Financials
| WXXWY Stock | USD 3.76 0.01 0.27% |
WuXi |
Understanding current and past WuXi Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of WuXi Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in WuXi Biologics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in WuXi Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of WuXi Biologics. Check WuXi Biologics' Beneish M Score to see the likelihood of WuXi Biologics' management manipulating its earnings.
WuXi Biologics Stock Summary
WuXi Biologics competes with Inhibikase Therapeutics, Corcept Therapeutics, Cardio Diagnostics, Revolution Medicines, and Nuvalent. WuXi Biologics Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the Peoples Republic of China, North America, Europe, and internationally. The company was incorporated in 2014 and is headquartered in Wuxi, China. Wuxi Biologics is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | No 108, Meiliang |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.wuxibiologics.com |
| Currency | USD - US Dollar |
WuXi Biologics Key Financial Ratios
WuXi Biologics' financial ratios allow both analysts and investors to convert raw data from WuXi Biologics' financial statements into concise, actionable information that can be used to evaluate the performance of WuXi Biologics over time and compare it to other companies across industries.| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Beta | 1.09 | |||
| Z Score | 32.4 |
WuXi Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining WuXi Biologics's current stock value. Our valuation model uses many indicators to compare WuXi Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across WuXi Biologics competition to find correlations between indicators driving WuXi Biologics's intrinsic value. More Info.WuXi Biologics is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.45 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for WuXi Biologics is roughly 2.23 . Comparative valuation analysis is a catch-all model that can be used if you cannot value WuXi Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for WuXi Biologics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.WuXi Biologics Systematic Risk
WuXi Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. WuXi Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on WuXi Biologics correlated with the market. If Beta is less than 0 WuXi Biologics generally moves in the opposite direction as compared to the market. If WuXi Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one WuXi Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of WuXi Biologics is generally in the same direction as the market. If Beta > 1 WuXi Biologics moves generally in the same direction as, but more than the movement of the benchmark.
WuXi Biologics December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of WuXi Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of WuXi Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of WuXi Biologics based on widely used predictive technical indicators. In general, we focus on analyzing WuXi Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build WuXi Biologics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.43 | |||
| Information Ratio | 0.1049 | |||
| Maximum Drawdown | 31.59 | |||
| Value At Risk | (6.62) | |||
| Potential Upside | 10.44 |
Additional Tools for WuXi Pink Sheet Analysis
When running WuXi Biologics' price analysis, check to measure WuXi Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WuXi Biologics is operating at the current time. Most of WuXi Biologics' value examination focuses on studying past and present price action to predict the probability of WuXi Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WuXi Biologics' price. Additionally, you may evaluate how the addition of WuXi Biologics to your portfolios can decrease your overall portfolio volatility.